Protein Aggregation : Clinical Chemistry and Laboratory Medicine Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R.


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

249,00 € / $374.00 / £187.00*

Online
ISSN
1437-4331
See all formats and pricing

 


Select Volume and Issue
Loading journal volume and issue information...

Protein Aggregation

Giampaolo Merlini / Vittorio Bellotti / Alessia Andreola / Giovanni Palladini / Laura Obici / Simona Casarini / Vittorio Perfetti

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 39, Issue 11, Pages 1065–1075, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2001.172, June 2005

Publication History

Published Online:
2005-06-01

Abstract

Protein aggregation occurs in vivo as a result of improper folding or misfolding. Diverse diseases arise from protein misfolding and are now grouped under the term “protein conformational diseases”, including most of the neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, the prion encephalopathies and Huntington's disease, as well as cystic fibrosis, sickle cell anemia and other less common conditions. The hallmark event in these diseases is a change in the secondary and/or tertiary structure of a normal, functional protein, leading to the formation of protein aggregates with various supramolecular organizations. In most cases the aggregates are organized in structurally well-defined fibrils forming amyloid deposits. The crucial feature of the amyloidogenic proteins is their structural instability induced either by mutations, post-translational modifications, or local conditions, such as pH, temperature, and co-solutes. The conformational change may promote the disease either by gain of a toxic activity or by the lack of biological function of the natively folded protein. As different molecular mechanisms are involved in the formation of the various forms of protein aggregates, the laboratory diagnostic approach remains frequently elusive.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Mojtaba Falahati, Ali Akbar Saboury, Abbas Shafiee, Seyed Mahdi Rezayat Sorkhabadi, Ehsan Kachooei, Leila Ma'mani, and Thomas Haertlé
Biophysical Chemistry, 2012, Volume 165-166, Page 13
[2]
Ai Yamamoto and Anne Simonsen
Neurobiology of Disease, 2011, Volume 43, Number 1, Page 17
[3]
Ritu Khurana, Pierre O. Souillac, Alisa C. Coats, Lauren Minert, Cristian Ionescu-zanetti, Sue A. Carter, Alan Solomon, and Anthony L. Fink
Amyloid, 2003, Volume 10, Number 2, Page 97
[4]
Kurosh Parsi and Steven Kossard
International Journal of Dermatology, 2004, Volume 43, Number 12, Page 925

Comments (0)

Please log in or register to comment.